Urokinase-controlled tumor penetrating peptide

Sugahara, 2009, Tissue-penetrating delivery of compounds and nanoparticles into tumors, Cancer Cell, 16, 510, 10.1016/j.ccr.2009.10.013 Teesalu, 2009, C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration, Proc. Natl. Acad. Sci. U. S. A., 106, 16157, 10.1073/pnas.0908201106 Sugahara, 2015, Tumor-penetrating iRGD peptide inhibits metastasis, Mol. Cancer Ther., 14, 120, 10.1158/1535-7163.MCT-14-0366 Atkinson, 2008, Tumour endoproteases: the cutting edge of cancer drug delivery?, Br. J. Pharmacol., 153, 1344, 10.1038/sj.bjp.0707657 Edwards, 2008, xxiii Andreasen, 2000, The plasminogen activation system in tumor growth, invasion, and metastasis, Cell. Mol. Life Sci., 57, 25, 10.1007/s000180050497 Ke, 1997, Optimal subsite occupancy and design of a selective inhibitor of urokinase, J. Biol. Chem., 272, 20456, 10.1074/jbc.272.33.20456 Blasi, 1997, uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?, Immunol. Today, 18, 415, 10.1016/S0167-5699(97)01121-3 Liu, 2001, Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin, J. Biol. Chem., 276, 17976, 10.1074/jbc.M011085200 Rono, 2006, Antitumor efficacy of a urokinase activation-dependent anthrax toxin, Mol. Cancer Ther., 5, 89, 10.1158/1535-7163.MCT-05-0163 Gerspach, 2006, Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface, Cancer Immunol. Immunother., 55, 1590, 10.1007/s00262-006-0162-6 Chung, 2006, Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA), Bioorg. Med. Chem. Lett., 16, 5157, 10.1016/j.bmcl.2006.07.023 Braun, 2014, Etchable plasmonic nanoparticle probes to image and quantify cellular internalization, Nat. Mater., 13, 904, 10.1038/nmat3982 Teesalu, 2012, Mapping of vascular ZIP codes by phage display, Methods Enzymol., 503, 35, 10.1016/B978-0-12-396962-0.00002-1 Sappino, 1991, Differential protease expression by cutaneous squamous and basal cell carcinomas, J. Clin. Invest., 88, 1073, 10.1172/JCI115406 Teesalu, 1996, Embryo implantation in mouse: fetomaternal coordination in the pattern of expression of uPA, uPAR, PAI-1 and alpha 2MR/LRP genes, Mech. Dev., 56, 103, 10.1016/0925-4773(96)00515-1 Pang, 2014, An endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availability, Nat. Commun., 5, 4904, 10.1038/ncomms5904 Mitra, 2006, Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model, Oncogene, 25, 4429, 10.1038/sj.onc.1209482 Zhang, 2005, Molecular profiling of heart endothelial cells, Circulation, 112, 1601, 10.1161/CIRCULATIONAHA.104.529537 Degryse, 2005, Domain 2 of the urokinase receptor contains an integrin-interacting epitope with intrinsic signaling activity: generation of a new integrin inhibitor, J. Biol. Chem., 280, 24792, 10.1074/jbc.M413954200 Bagri, 2009, Neuropilins in tumor biology, Clin. Cancer Res., 15, 1860, 10.1158/1078-0432.CCR-08-0563 Petitclerc, 1999, Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival, Cancer Res., 59, 2724 Sugahara, 2010, Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs, Science, 328, 1031, 10.1126/science.1183057 Jiang, 2004, Tumor imaging by means of proteolytic activation of cell-penetrating peptides, Proc. Natl. Acad. Sci. U. S. A., 101, 17867, 10.1073/pnas.0408191101 Aguilera, 2009, Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides, 1, 371 Nguyen, 2010, Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival, Proc. Natl. Acad. Sci. U. S. A., 107, 4317, 10.1073/pnas.0910261107 Pang, 2015, Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized with cationic cell-penetrating peptides, Sci. Adv., 1, 10.1126/sciadv.1500821 Zhu, 2012, Matrix metalloprotease-2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting, ACS Nano, 6, 3491, 10.1021/nn300524f Herter, 2005, Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers, Biochem. J., 390, 125, 10.1042/BJ20041955 Wu, 2007, Hepsin and prostate cancer, Front. Biosci., 12, 5052, 10.2741/2447 Lee, 2000, Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease, J. Biol. Chem., 275, 36720, 10.1074/jbc.M007802200 List, 2006, Matriptase: potent proteolysis on the cell surface, Mol. Med., 12, 1, 10.2119/2006-00022.List Uhland, 2006, Matriptase and its putative role in cancer, Cell. Mol. Life Sci., 63, 2968, 10.1007/s00018-006-6298-x